Celltrion Plans to Initiate P-I Trial for its CT-P41 (biosimilar, denosumab) in September 2020

 Celltrion Plans to Initiate P-I Trial for its CT-P41 (biosimilar, denosumab) in September 2020

Celltrion Initiates P-I Study of its COVID-19 Antibody Treatment in South Korea

Shots:

  • In H1’21, Celltrion plans to initiate P-III trial for CT-P41 and is expected to commercialize in Feb 2025 when Amgen’s patents for Prolia expire in the US
  • Celltrion is also planning for the onset of P-III for CT-P16 in H1’21 targeted for metastatic colorectal cancer, metastatic breast cancer, and non–small cell lung cancer. Additionally, one of its biosimilar CT-P39 is currently evaluated in P-I trial with expected P-III trial initiation in 2022
  • CT-P41 is a mAb a biosimilar to Amgen Prolia (denosumab) targets receptor activator of nuclear factor-kappa-Β ligand (RANKL) proteins in patients with osteoporosis

Click here to read full press release/ article | Ref: Celltrion | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post